Literature DB >> 25616634

Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome.

Jack F M Wetzels1, Nicole C A J van de Kar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25616634     DOI： 10.1053/j.ajkd.2014.04.039

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  15 in total

Review 1.  Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications.

Authors:  Shruti Chaturvedi; Evan M Braunstein; Robert A Brodsky
Journal:  J Thromb Haemost       Date:  2021-02-10       Impact factor: 5.824

2.  Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

Authors:  Fadi Fakhouri; Marc Fila; François Provôt; Yahsou Delmas; Christelle Barbet; Valérie Châtelet; Cédric Rafat; Mathilde Cailliez; Julien Hogan; Aude Servais; Alexandre Karras; Raifah Makdassi; Feriell Louillet; Jean-Philippe Coindre; Eric Rondeau; Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-31       Impact factor: 8.237

3.  Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome.

Authors:  Shruti Chaturvedi; Noor Dhaliwal; Sarah Hussain; Kathryn Dane; Harshvardhan Upreti; Evan M Braunstein; Xuan Yuan; C John Sperati; Alison R Moliterno; Robert A Brodsky
Journal:  Blood Adv       Date:  2021-03-09

Review 4.  Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2021-05-05       Impact factor: 28.314

Review 5.  Can eculizumab be discontinued in aHUS?: Case report and review of the literature.

Authors:  Tuncay Sahutoglu; Taner Basturk; Tamer Sakaci; Yener Koc; Elbis Ahbap; Mustafa Sevinc; Ekrem Kara; Cuneyt Akgol; Feyza Bayraktar Caglayan; Abdulkadir Unsal; Mohamed R Daha
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 6.  Atypical Hemolytic Uremic Syndrome: A Brief Review.

Authors:  Kuixing Zhang; Yuxin Lu; Kevin T Harley; Minh-Ha Tran
Journal:  Hematol Rep       Date:  2017-06-01

7.  Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.

Authors:  Manuel Macia; Fernando de Alvaro Moreno; Tina Dutt; Ingela Fehrman; Karine Hadaya; Christoph Gasteyger; Nils Heyne
Journal:  Clin Kidney J       Date:  2016-12-22

Review 8.  Critical appraisal of eculizumab for atypical hemolytic uremic syndrome.

Authors:  Lilian M Pereira Palma; Craig B Langman
Journal:  J Blood Med       Date:  2016-04-12

Review 9.  Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in de novo and recurrent diseases.

Authors:  Fedaey Abbas; Mohsen El Kossi; Jon Jin Kim; Ihab Sakr Shaheen; Ajay Sharma; Ahmed Halawa
Journal:  World J Transplant       Date:  2018-10-22

10.  Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality.

Authors:  Gianluigi Ardissino; Selena Longhi; Luigi Porcaro; Giulia Pintarelli; Bice Strumbo; Valentina Capone; Donata Cresseri; Giulia Loffredo; Francesca Tel; Stefania Salardi; Martina Sgarbanti; Laura Martelli; Evangeline Millicent Rodrigues; Nicolò Borsa-Ghiringhelli; Giovanni Montini; Manuela Seia; Massimo Cugno; Fabio Carfagna; Dario Consonni; Silvana Tedeschi
Journal:  Kidney Int Rep       Date:  2021-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.